AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals aims for over $300 million in revenue by FY27 after reporting record earnings and 22% revenue growth to $254.7 million for FY26. Operating profit reached $24.4 million, exceeding guidance, while net profit rose 24% to $14.1 million. The company is expanding internationally, with significant growth in Asia and plans for new product launches. AFT is also increasing R&D investment to $25 million in FY27, focusing on unmet clinical needs and diversifying its product portfolio.

Small Caps

Hikma Pharmaceuticals Plc

AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings

AFT Pharmaceuticals has appointed Stuart Houliston as the new CFO, effective June 15, 2026, succeeding Malcolm Tubby. Houliston, previously with Sanford and KPMG, is expected to enhance the company's global growth strategy. AFT Pharmaceuticals is New Zealand's largest pharmaceutical company, offering a wide range of medicines across various markets.

Tip Ranks

AFT Pharmaceuticals appoints new CFO to support global growth

The NZX 50 rose 93 points (0.7%) to 12,996 in morning trade, following a two-day Easter closure and extending previous gains. The index reached its highest level since March 19, buoyed by positive Wall Street sentiment and expectations that the RBNZ will maintain interest rates at 2.25%. Almost all sectors were up, with notable gains from AFT Pharmaceuticals (2.1%) and Fisher & Paykel Healthcare (1.6%). Investors are also awaiting US March inflation data amid rising energy prices.

Trading Economics

New Zealand Stocks Track Wall Street Higher

Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results

Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results

AFT Pharmaceuticals faces change in CFO succession plan

BlackRock, Inc.

AFT Pharmaceuticals faces change in CFO succession plan

VRTX

ATYR

AFT Pharmaceuticals has won a Court of Appeal ruling in New Zealand, dismissing PBL Solutions' claim for profit-sharing from the use of its skin medicine Pascomer for non-orphan indications. The judgment confirms that profit-sharing is limited to orphan drug applications, ensuring AFT retains control over the more lucrative Port Wine Stain market. AFT does not anticipate any significant impact on its FY 2026 earnings guidance, providing clarity for investors regarding future returns from this asset.

Vertex Pharma

ATYR Pharma

AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute

SBIO

Faron Pharmaceuticals Ltd. announced that data from its Phase I/II BEXMAB trial on bexmarilimab, in combination with azacitidine for treating higher-risk myelodysplastic syndromes (MDS), has been accepted for poster presentation at the 66th Annual Scientific Meeting of the British Society for Haematology (BSH) in April 2026. The presentation will include updated results from the trial, supporting the advancement of bexmarilimab into the next development phase. The company aims to engage with the hematology community and share insights on the treatment's safety and efficacy.

MorningStar

ALPS Medical Breakthrough

VG Health

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Forte Biosciences

VanEck Biotech ETF

iShares Global Healthcare

iShares Biotechnology ETF

Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

The NZX 50 rose 1.3%, closing at 13,420, driven by gains in financials, healthcare, non-energy minerals, and logistics. This increase followed signals from New Zealand's central bank regarding potential policy adjustments to control inflation. The RBNZ maintained rates at 2.25%, with future hikes dependent on inflation and economic growth. Positive sentiment was also supported by a rise in U.S. futures and Wall Street's rebound. However, caution prevailed ahead of upcoming trade balance and retail sales data. Notable performers included AFT Pharmaceuticals, Chorus Ltd., EBOS Group, and Fisher & Paykel Healthcare.

EBOS Group Limited

Fisher & Paykel Healthcare Corporation Limited

Chorus Limited

NZX 50 Jumps 1.3% at Finish

Faron Pharmaceuticals has expanded its clinical trials for bexmarilimab, an investigational immunotherapy, to include a randomized Phase I/II trial (BEXAR IIT) for metastatic soft-tissue sarcoma. Conducted in collaboration with MEDSIR and University Hospital Vall d'Hebron, the trial aims to evaluate the combination of bexmarilimab and doxorubicin in patients with high unmet needs. The study seeks to reprogram immunosuppressive macrophages to enhance chemotherapy efficacy, addressing the urgent need for improved treatment options in this aggressive cancer type.

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

AFT Pharmaceuticals Ltd.(AFP.AU)

AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings

AFT Pharmaceuticals appoints new CFO to support global growth

New Zealand Stocks Track Wall Street Higher

Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results

AFT Pharmaceuticals faces change in CFO succession plan

AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute

Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

NZX 50 Jumps 1.3% at Finish

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma